Af­ter wind­ing down Quench Bio with a bold dose of hon­esty, Sam Truex finds 'per­fect fit' at At­las Ven­ture

5 years ago
People

British CRO wins con­tract for Covid-19 chal­lenge virus; Dutch agency aims to slash Zol­gens­ma prices in half

5 years ago
News Briefing

Ahead of Nas­daq de­but, Saurabh Sa­ha pads out the C-suite at Centes­sa, hir­ing a top Dai­ichi Sankyo alum as CMO

5 years ago
People

Bay­er claims an­oth­er win on its CKD and di­a­betes hope­ful, though the ques­tion re­mains over just how big it is

5 years ago
R&D

Biden ad­min­is­tra­tion sig­nals that FDA may al­low abor­tion pill ac­cess via mail even af­ter the pan­dem­ic

5 years ago
FDA+

Ab­b­Vie makes a hefty play to boost aes­thet­ics busi­ness, pay­ing $550M for non-in­va­sive body sculpt­ing de­vice

5 years ago
Deals
Pharma

Io­n­is scraps CF pro­gram in an­oth­er set­back for the dis­ease and the com­pa­ny

5 years ago
R&D

BioN­Tech ex­pands mR­NA man­u­fac­tur­ing to Sin­ga­pore as clam­or for Covid-19 vac­cine and boost­ers swells

5 years ago
Manufacturing

Per­cep­tive's $310M US/Chi­na play woos new CEO from Eli Lil­ly's top-speed bam­lanivimab team

5 years ago
People

Covid-19 roundup: No­vavax may not go to FDA un­til June at ear­li­est — re­port; Bourla push­es back against IP waiv­er ...

5 years ago
Coronavirus

Saman­tha Du's Quan Cap­i­tal, Lil­ly Asia back Chi­na's first big kid­ney play

5 years ago
Financing
China

The com­pa­ny be­hind Mod­er­na has a new RNA start­up look­ing to dis­rupt drug­mak­ing. The goal? 100 new drugs in 10 years

5 years ago
Financing
Startups

Ex-Har­vard pro­fes­sor and se­r­i­al en­tre­pre­neur Omid Farokhzad jumps in­to the SPAC game with some in­dus­try in­sid­ers and ...

5 years ago
Financing

Let’s make that $1B-plus: Abing­worth gath­ers more cash, this time for its late-stage pok­er game. And we learned ...

5 years ago
Financing
Bioregnum

As­traZeneca, Dai­ichi Sankyo un­cork new TNBC da­ta for 2nd part­nered ADC — and it's adding more heat un­der Gilead­'s ...

5 years ago
R&D

Roger Perl­mut­ter’s new gig, Covid-19 IP dra­ma, Vivek Ra­maswamy's coach on the SPAC train, and more

5 years ago
Weekly

An­oth­er failed tri­al for Or­p­hazyme's 'pipeline-in-a-pro­duc­t' leaves shad­ow on drug's fu­ture

5 years ago
R&D

In­cyte ponies up $12M to set­tle char­i­ty foun­da­tion kick­back claims; US ex­er­cis­es op­tion for more dos­es of mon­key­pox ...

5 years ago
News Briefing

Hours be­fore ex­pect­ed de­but, Gy­ro­scope post­pones its IPO as 2 oth­er biotechs hold the line on their march to Nas­daq

5 years ago
Financing

Covid-19 roundup: Pfiz­er sub­mits vac­cine for full ap­proval; Merkel op­pos­es Biden pro­pos­al to sus­pend IP for vac­cines

5 years ago
Pharma
Coronavirus

Karyopharm taps long­time Pfiz­er, Am­gen vet to steer the ship; With Mer­ck in the rearview mir­ror, Roger Perl­mut­ter ...

5 years ago
Peer Review

Amid vir­tu­al tri­al craze, Sci­ence 37 earns uni­corn sta­tus and a trip to Nas­daq on the back of SPAC deal

5 years ago
Financing

EMA safe­ty com­mit­tee seeks more in­fo on heart in­flam­ma­tion fol­low­ing Pfiz­er Covid-19 vac­cine

5 years ago
FDA+
Coronavirus

As­traZeneca caps PD-L1/CT­LA-4/chemo com­bo come­back with OS win. Is treme­li­mum­ab fi­nal­ly ready for ap­proval?

5 years ago
R&D
Pharma
First page Previous page 695696697698699700701 Next page Last page
A service from the Financial Times